ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 4 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.


Player Avatar chall77 (< 20) Submitted: 2/1/2014 6:40:50 PM : Outperform Start Price: $2.30 ARQL Score: -60.02

I understand they have a promising liver drug on the way that is supposed to be a strong performer for the company

Featured Broker Partners